Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0001645,
umls-concept:C0004147,
umls-concept:C0021308,
umls-concept:C0039005,
umls-concept:C0077786,
umls-concept:C0205147,
umls-concept:C0277785,
umls-concept:C0392756,
umls-concept:C0450442,
umls-concept:C0456389,
umls-concept:C0475224,
umls-concept:C0599946,
umls-concept:C1522564,
umls-concept:C1707455
|
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-6-22
|
| pubmed:abstractText |
Heart rate (HR) is a major factor determining the severity of myocardial ischemia, and HR reduction is an effective therapy for myocardial ischemia. We tested the effects of HR reduction induced by either UL-FS 49 or atenolol on regional myocardial blood flow, function, and infarct size (IS) in a porcine model of 90-min low-flow ischemia and 2-h reperfusion. In 24 Göttinger miniswine, the left anterior descending coronary artery (LAD) was cannulated and hypoperfused at constant inflow to reduce anterior systolic wall thickening (AWT, sonomicrometry) by approximately 85%. Eight swine served as a placebo group, and 8 other swine received UL-FS 49 (0.60 mg/kg intravenously, i.v.) after 10-min ischemia. In the remaining 8 swine, atenolol was infused after 10-min ischemia at a dosage [mean 1.75 +/- 1.20 (SD) mg/kg i.v.] to mimic the HR reduction observed with UL-FS 49. Systemic hemodynamics, subendocardial blood flow (ENDO, microspheres) and AWT were measured under control conditions, at 10 and 90 min of ischemia. In the swine receiving UL-FS 49 or atenolol, additional measurements were made 5 min after administration of the respective drug. After 2-h reperfusion, IS (percentage of area at risk) was determined with TTC-staining. Five minutes after administration of UL-FS 49, HR was decreased from 113 +/- 9 to 83 +/- 13 beats/min (p < 0.05) and remained unchanged when ischemia was prolonged to 90 min. In the swine receiving atenolol, HR was reduced from 117 +/- 14 to 93 +/- 7 beats/min (p < 0.05) 5 min after drug administration and decreased further to 87 +/- 10 beats/min when ischemia was prolonged to 90 min. After 10 min of ischemia, AWT in the placebo, UL-FS 49, and atenolol group was decreased to 7.0 +/- 5.5, 6.4 +/- 3.5, and 6.2 +/- 3.3% (all p < 0.05 vs. control), respectively. The reduction in ENDO was also comparable among the three groups. In the placebo group, AWT remained unchanged when ischemia was prolonged to 90 min (4.4 +/- 2.6%). In swine receiving atenolol, AWT tended to increase (13.6 +/- 10.5%), whereas in swine receiving UL-FS 49, AWT was significantly increased to 21.4 +/- 7.1% (p < 0.05 vs. 10-min ischemia and vs. the placebo and atenolol groups). IS was significantly reduced in swine receiving atenolol (3.9 +/- 3.5%) or UL-FS 49 (5.8 +/- 4.6%) as compared with the placebo-group (10.4 +/- 8.9%).(ABSTRACT TRUNCATED AT 400 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Triphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Atenolol,
http://linkedlifedata.com/resource/pubmed/chemical/Benzazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Cardiovascular Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Lactates,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphocreatine,
http://linkedlifedata.com/resource/pubmed/chemical/zatebradine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0160-2446
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
216-28
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7752647-Adenosine Triphosphate,
pubmed-meshheading:7752647-Animals,
pubmed-meshheading:7752647-Atenolol,
pubmed-meshheading:7752647-Benzazepines,
pubmed-meshheading:7752647-Blood Pressure,
pubmed-meshheading:7752647-Bradycardia,
pubmed-meshheading:7752647-Cardiovascular Agents,
pubmed-meshheading:7752647-Coronary Circulation,
pubmed-meshheading:7752647-Disease Models, Animal,
pubmed-meshheading:7752647-Female,
pubmed-meshheading:7752647-Heart,
pubmed-meshheading:7752647-Heart Rate,
pubmed-meshheading:7752647-Injections, Intravenous,
pubmed-meshheading:7752647-Lactates,
pubmed-meshheading:7752647-Male,
pubmed-meshheading:7752647-Myocardial Infarction,
pubmed-meshheading:7752647-Myocardial Ischemia,
pubmed-meshheading:7752647-Myocardium,
pubmed-meshheading:7752647-Oxygen Consumption,
pubmed-meshheading:7752647-Phosphocreatine,
pubmed-meshheading:7752647-Reperfusion Injury,
pubmed-meshheading:7752647-Swine,
pubmed-meshheading:7752647-Swine, Miniature
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol.
|
| pubmed:affiliation |
Abteilung für Pathophysiologie, Universitätsklinikum Essen, German.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|